1 Higher Perceived Stress during the COVID-19 pandemic increased Menstrual **Dysregulation and Menopause Symptoms** 2 3 4 Romina Garcia de Leon¹, Alexandra Baaske², Arianne Y Albert² PhD, Amy Booth^{2,6}, C. 5 Sarai Racey^{2,6}, Shanlea Gordon², Laurie W. Smith, Anna Gottschlich^{2,6}, Manish 6 Sadarangani^{4,5} MD, Angela Kaida^{2,3} PhD, Gina S, Ogilvie^{2,6} MD, Lori A, Brotto^{2,7,*} PhD. 7 Liisa A.M. Galea^{1,8,9} PhD 8 9 ¹Graduate Program in Neuroscience, University of British Columbia, Vancouver, Canada. 10 ²Women's Health Research Institute, Vancouver, Canada 11 ³Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada 12 ⁴Department of Pediatrics, University of British Columbia, Vancouver, Canada. 13 ⁵Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, 14 Canada. 15 ⁶School of Population and Public Health, University of British Columbia, Vancouver, 16 17 Canada. ⁷Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, 18 19 Canada. ⁸Department of Psychology, University of British Columbia, Vancouver, Canada. 20 ⁹ Djavad Mowafaghian Centre for Brain Health, University of British Columbia 21 & Department of Pathology and Laboratory Medicine, University of British Columbia, 22 23 Vancouver, Canada. 24 25 26 *Correspondence can be addressed to: 27 28 Dr. Liisa Galea Diavad Mowafaghian Centre for Brain Health 29 University of British Columbia 30 31 2215 Wesbrook Mall 32 Vancouver, BC, Canada V6T 1Z3 33 34 liisa.galea@ubc.ca

39 40

41

42 43

44 45

46

47

48

49

50

51

52

53

54

55 56

57

58 59

60 61 62

63 64 65 **Statements and Declarations** Funding: Funding for this project was from a Michael Smith Foundation for Health Research Grant (19055) and a BC Women's Health Foundation Grant (LRZ30421) both awarded to LAB and GSO. Additional support was provided by CIHR (PJT-148662) awarded to LAMG. Competing Interests The authors have no competing interests to declare that are relevant to the content of this article. Ethical Approval Ethical approval was received from the BC Children's and Women's Research Ethics board (H20–01421). All methods performed as a part of this study were in accordance with the UBC Research Ethics Board guidelines. Informed consent to participate was obtained from participants. Data Availability Data cannot be shared publicly because of ethical restrictions. Data are available from the UBC Research Ethics Board (contact via cwreb@bcchr.ubc.ca) for researchers who meet the criteria for access to confidential data. Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Arianne Albert, Amy Booth, Shanlea Gordon, Alexandra Baaske and Romina Garcia de Leon. The first draft of the manuscript was written by Romina Garcia de Leon, Alexandra Baaske, and Liisa Galea and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Acknowledgements We thank David M. Goldfarb and Melanie Murray for their contributions to this work.

66 Abstract

Purpose

The increased stress the globe has experienced with the COVID-19 pandemic has affected mental health, disproportionately affecting women. However, how perceived stress in the first year affected menstrual and menopausal symptoms has not yet been investigated.

Methods Residents in British Columbia, Canada, were surveyed online as part of the COVID-19 Rapid Evidence Study of a Provincial Population-Based Cohort for Gender and Sex (RESPPONSE). A subgroup (n=4171) who were assigned female sex at birth (age 25-69) and were surveyed within the first 6-12 months of the pandemic (August 2020-February 2021), prior to the widespread rollout of vaccines, were retrospectively asked if they noticed changes in their menstrual or menopausal symptoms, as well as completing validated measures of stress, depression, and anxiety.

Results We found that 27.8% reported menstrual cycle disturbances and 6.7% reported increased menopause symptoms. Those who scored higher on perceived stress, depression, and anxiety scales were more likely to have reproductive cycle disturbances. Free text responses revealed that reasons for disturbances were perceived to be related to the pandemic.

Conclusions The COVID-19 pandemic has highlighted the need to research women's health issues, such as menstruation. Our data indicates that in the first year of the pandemic, almost a third of the menstruating population reported disturbances in their cycle, which is approximately two times higher than in non-pandemic situations and four times higher than any reported changes in menopausal symptoms across that first year of the pandemic.

Keywords anxiety; depression; women; reproductive cycles; stress; COVID-19

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134135

136

137

138

139

140

The COVID-19 pandemic led to closures of public places, strict health regulations, and limited social interactions. These changes, along with the uncertainty of the pandemic, resulted in increased perceived levels of stress, depression, and anxiety (Brotto et al., 2021; Kujawa et al., 2020). Women and gender diverse individuals exhibited greater indices of distress, including heightened risk for mental health disorders than men throughout the COVID-19 pandemic (Brotto et al., 2021; Connor et al., 2020; Hunt et al., 2021). Despite these findings, there has been minimal attention paid to the effects of sex and gender in COVID-19 studies (Brady et al., 2021; Ciarambino et al., 2021; Edelman et al., 2022). There has been a lack of research on the specific impact of SARS-CoV-2 vaccines, and pandemic response on female health (Sharp et al., 2021) which has contributed to alarming anecdotal reports of menstrual cycle irregularities following COVID-19 vaccination on social media (Male, 2021). These reported incidents underscored the importance of studying female cycles, which are now being closely examined in relation to COVID-19 vaccination (Edelman et al., 2022; Lee et al., 2021; Trogstad, 2022). However, there remains a need to examine the overall impact of the pandemic response on female menstrual cycles. Menstrual cycle irregularities, perimenopause, and menopausal disturbances can be important indicators of overall physical health (Alvergne & Höggvist Tabor, 2018). Menstrual cycle irregularity is linked to metabolic dysfunction (Souza et al., 2010) and increased risk of cardiovascular disease (Solomon et al., 2002). Furthermore, vasomotor menopausal symptoms are related to white matter hyperintensities and cognitive disturbances (Thurston et al., 2016). Exposure to stress affects the hypothalamic pituitary gonadal (HPG) axes (Viau, 2002) as higher perceived stress is correlated with menopausal symptoms (Nosek et al., 2010; Weidner et al., 2020) and menstrual dysregulation (Nagma et al., 2015). Thus, it is not surprising that the COVID-19 pandemic and the associated increase in stress has led to reports of disturbances to menstrual cycles (Phelan et al., 2021). Premenopausal people have reported irregularities in their menstrual cycles across different phases of the COVID-19 pandemic (Demir et al., 2021), consistent with the literature indicating that heightened perceived stress is a predictor for menstrual

irregularities (Yamamoto et al., 2009). Prolonged stress is also associated with an increased risk for psychiatric disorders (McEwen & Akil, 2020) and females reported higher depressive symptoms than males during the COVID-19 pandemic (Brotto et al., 2021; Pieh et al., 2020). Moreover, studies show that depressed mood is associated with menstrual irregularities (Yu et al., 2017), meaning that pandemic-related stress may be affecting mental health and menstrual irregularities simultaneously or sequentially. Given that stress and menstrual irregularities are connected (Yamamoto et al., 2009), and may play a role in mental health disturbances (Yu et al., 2017), it is important to study these relationships.

Heightened stress would likely have an impact on menstrual/menopausal irregularities, but to our knowledge no study to date has examined these irregularities in relation to psychosocial outcomes such as perceived stress, anxiety, or depression scores, and other factors that may play a role in perceived stress (age, number of children) within the context of the COVID-19 pandemic. We hypothesized that females would report an increase in the number of menstrual and menopausal symptoms during the first year of the pandemic, and secondly that these disturbances would be associated with stress, anxiety and depression levels.

Methods

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

Participant Recruitment

- The Rapid Evidence Study of a Provincial Population Based COhort for GeNder and SEx (RESPPONSE) was led by the Women's Health Research Institute in British
- 163 Columbia (BC). All participants provided informed consent prior to participation in
- 164 RESPPONSE. Ethics approval was received from The BC Children's and Women's
- Research Ethics Board (H20-01421). Between mid-August 2020 and March 1, 2021,
- participants were recruited (Ogilvie et al., 2021). Survey responses were collected
- anonymously, with the exception of postal code. All respondents who completed the
- survey were invited to enter a draw to win a \$100 e-gift card.
- The survey was open to residents of BC aged 25 to 69 years of all sexes and genders.
- However, only participants who were assigned female sex at birth were eligible for this

particular analysis (n=5608). For analyses pertaining to menstrual changes, eligibility was restricted to: female sex, not post-menopausal, not pregnant, first six months postpartum, and not on hormonal suppression drugs (n=1866). In addition, we also conducted sensitivity analyses for menstrual changes to those people under 40 to avoid conflation with possible symptoms of perimenopause (n=810). For analyses of menopausal symptoms, eligibility was restricted to female sex and those who responded that they were postmenopausal (n=2305). In addition, we also conducted sensitivity analyses for menopause status to those people over 50 (n=1978) to avoid conflation with possible symptoms of perimenopause.

Survey Design and Measures

171

172

173

174

175

176

177

178179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

The survey was tested for face validity, pilot tested, and implemented using REDCap (Research Electronic Data Capture) (Harris et al., 2009). The survey consisted of multiple modules, with the present analysis focused on female reproductive health questions surrounding menstrual cycle and menopause symptoms.

All survey participants that were premenopausal were asked "Since the COVID-19 pandemic and subsequent public health measures in mid-March 2020, have you noticed any changes to your menstrual cycle? (yes/no/not applicable due to hormonal suppression/not applicable other)", and participants that were postmenopausal were asked "Have you noticed any changes to your postmenopausal status since mid-March 2020? (yes/no)." Respondents who indicated changes to their menstrual cycle or postmenopausal status were prompted to check all that applied from a list of changes and provided with a free-text box (Survey available in Supplemental Section). All freetext responses were coded with thematic analysis using the methods outlined in Braun & Clarke (2006) to examine the potential variables influencing these changes. All responses were assigned to one of two main themes: 'Non-pandemic related' and 'Pandemic control measures.' "Non-pandemic related" comments were obvious changes to their health and reproductive system at the start of the pandemic or preceding the pandemic. Alternatively, specific mentions of changes to their status or cycle, without medical reason, and stated as due to the pandemic were categorized as pandemic-related. After separating all responses into these two themes, sub-themes

were created to identify reproductive changes that occurred during the pandemic. Subthemes were created if one or more respondents expressed the same theme in their free-text response.

Validated scores of general pandemic stress, anxiety, and depression were measured (Huang et al., 2006; Löwe et al., 2008). General pandemic stress was measured using the CoRonavIruS Health Impact Survey (CRISIS) V0.3. Participants were asked to self-report feelings of stress on a Likert scale from one (not at all) to five (extremely). Scores for this questionnaire range from 10–50 with higher scores indicating greater COVID-related stress.

Anxiety scores were calculated using the Generalized Anxiety Disorder questionnaire (GAD-7) The GAD-7 used self-reported feelings of anxiety on a Likert scale from zero (not at all) to three (nearly everyday) with scores ranging from 0–21. Scores above 10 suggest clinically significant levels of anxiety (Spitzer et al., 2006).

The Patient Health Questionnaire (PHQ-9) was used to measure self-reported symptoms of depression on a Likert scale from zero (not at all) to three (nearly everyday). Scores range from 0–27 with a score of 0–4 indicating minimal depression, 5–14 indicating mild to moderate depression and 15–27 indicating moderately severe to severe depression (Brotto et al., 2021).

Internal consistency across data collection and Cronbach's alpha in the current sample was very good (CRISIS: α = 0.882; GAD-7: 0.889, PHQ: α = 0.848).

Statistical Analyses

Analyses were carried out using R v.4.1.3. (Core Team, 2022). The data set was divided into two separate groups: people with menstrual periods and those in menopause (postmenopause) as described above and summarized the percentages of those with any changes noted. We examined the relationship between mental health and changes in menopause status or menstruation using mixed-effects linear regression models with individual as random effects, and controlling for age. Significance was assessed using likelihood-ratio tests, and interactions were removed from the models if non-significant at p < .05. Post-hoc pairwise tests were conducted to

232

233

234

235

236

237

238

239

240

241

242243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

further explore main or interaction effects with Tukey adjusted p-values. Missing data were excluded from analyses. Results **Survey Participants** Demographic information (age, ethnicity, gender, number of adults or children in the household, education, etc.) is seen in Table 1. Of the premenopausal participants, 98.4% identified as women, 0.1% identified as men and 1.5% as gender diverse. Of the postmenopausal participants, 99% identified as women, 0.1% identified as men and 0.8% as gender diverse. Given that nearly all females also identified as women, we have chosen to use the term women+ to refer to participants in our survey. **Changes in menstrual symptoms** Among our sample of premenopausal women+, 519 (27.8% of the sample without suppressed cycles) reported that they had noticed changes in their menstrual cycle since March 2020. Of these 519 respondents, 44.3% indicated that their periods were more symptomatic (painful, more bleeding, etc.), 25.4%% indicated that their periods were longer, 23.7%% said they were having fewer periods than before the pandemic, 21.8% noticed having more periods than normal, 15.7% said their periods had gotten shorter, 2.3% said their periods were less symptomatic. Options were not mutually exclusive and we received 784 answers from a potential 519 respondents. Moreover, 17.8% used free-text space to explain the changes to their menstrual cycles that they had noticed. The analysis of the free text responses indicated that there were twice as many respondents that indicated their changes in symptoms were due to the *Pandemic* control measures(Table 2). As those aged >40 years are more likely to be experiencing perimenopause, which could create menstrual disturbances independent of psychosocial stress, we undertook a sensitivity analysis of those who were less than 40 years old. Of this subset (n=810),

29.2% (n=237) reported changes in their menstrual cycle since the pandemic began. In

addition, 52.7% indicated that their periods were more symptomatic (painful, more bleeding, etc.), 32.1% indicated that their periods had gotten longer, 13.1% said they were having fewer periods than normal, 20.7% noticed having more periods than normal, 19.0% said their periods had gotten shorter, 2.1% said their periods were less symptomatic, and 19.8% used free-text space to explain the changes to their menstrual cycles that they had noticed. Options were not mutually exclusive and we received 378 answers from a potential 237 respondents.

Changes in menopausal symptoms

Among our sample of postmenopausal females (n = 2305), 155 (6.7%) reported that they noticed changes in their postmenopausal status since mid-March 2020. Of this subset (n=155), 16.1% indicated that they started bleeding again and 12.3% indicated that they were experiencing "more menstrual symptoms". Additionally, 72.9% used free-text space to explain the changes to their postmenopausal status. The analysis of the free-text responses revealed that there were four times as many respondents that indicated changes to postmenopausal status falling into the "due to the pandemic control measures" category (Table 3).

As those aged <50 years are more likely to be experiencing perimenopause, which could create menopausal disturbances independent of psychosocial stress, a sensitivity analysis that restricted to those ≥50 (n = 1978) was conducted. Of this subset, there were 127 (6.4%) who reported that they had noticed changes in their postmenopausal status since before the pandemic. Of this subset (n=127), 18.1% indicated that they started bleeding again and 7.9% indicated that they were experiencing "more menstrual symptoms". Additionally, 71.7% of this subset used free-text space to explain the changes to their postmenopausal status that they had noticed. Analysis of these free-text responses revealed that 19.8% of reported changes were associated with the onset of the pandemic and 80.1% were not not pandemic-related.

Higher pandemic stress, anxiety, and depression symptoms were related to more disturbances in menstrual and menopausal symptoms

We next examined whether any changes to menstrual or menopause symptoms were related to anxiety, depression, or perceived stress. We found that across both groups, more disturbances in their cycles indicated they scored higher on each of the psychosocial measures, with premenopausal women+ scoring higher than postmenopausal women+. For premenopausal women+ pandemic stress were 3.9 (95%CI:3.1-4.8) points higher, anxiety scores were 2.0 (95%CI: 1.6-2.4) points higher, and depression scores were 2.4 (95%CI: 2.0-2.8) points higher on average in those that reported menstrual cycle disturbances(Figure 1 A-C). For postmenopausal women+, pandemic stress scores were 2.9 (95%CI: 1.9-3.9) points higher, anxiety scores were 1.5 (95%CI: 0.9-2.1) points higher, depression scores were 1.8 (95%CI: 1.2-2.5) points higher on average in those that reported changes to their menopausal status (Figure 1D-F).

Relationship of menstrual or postmenopausal disturbances to number of children

As previous studies have found an association between number of children and stress (Bigalke et al., 2020), we also examined whether the number of children influenced our results. We ran these analyses in premenstrual women+ that were under 40, choosing to exclude individuals who may have been perimenopausal based on age. There was no significant relationship between the number of children and whether or not the participant indicated they had disturbances to their menstrual cycle (p=0.100). We next examined whether or not there was a relationship between menopausal disturbances and the number of children. There was a significant relationship (p=0.007), however when we used age as a covariate the effect was no longer significant (p=0.409). There were also no significant relationships between the number of children and pandemic stress scores, after controlling for age and changes to menstruation or menopause (p=0.167 and 0.400, respectively).

Discussion

In a sample of 4171 surveyed women+ in BC that met our inclusion criteria, 27.8% of naturally cycling women+ had a disruption in their menstrual cycle and 6.7% of

postmenopausal women+ indicated a change in their status, across the first year of the COVID-19 pandemic and prior to widespread rollout of COVID-19 vaccines. These disturbances to the reproductive cycles were related to higher levels of anxiety, depression, and perceived stress, but not to the number of children, in both pre and postmenopausal women+. Premenopausal women+ with menstrual cycle phase disturbances scored higher on perceived stress (3.4 points), anxiety (2.0) and depression (2.4) measures. We previously found that women had higher levels of perceived stress, depression, and anxiety compared to men, using data from the same source (Brotto et al., 2021). Our findings here indicate that both pre and postmenopausal women+ with higher levels of mental distress experienced greater disturbances in reproductive cycles. Stress has pervasive effects on mental and physical health and our results add to the growing data that female-specific reproductive cycles are also affected.

During the first year of the pandemic menstrual cycle disturbances were related to distress, anxiety and depression.

We found that in the first year of the pandemic, 27.8% of the naturally-cycling women+ surveyed had disturbances to their menstrual cycles. This is slightly lower than other surveys suggesting that 44% of women (including women that were younger than our own cohort 18-24) noticed changes in their cycles using fertility tracking devices (Buran & Gerçek Öter, 2022; Haile et al., 2022). Other studies have suggested that the baseline rates of menstrual disturbances are ~15% (Toffel et al., 2013, Kim et al., 2018). Premenopausal women in our study with reported menstrual disturbances had 3.4 times higher perceived stress. Our findings are consistent with another study that showed an association between perceived stress during the COVID-19 pandemic and menstrual irregularities (Ozimek et al., 2022). Although the literature suggests that parental responsibility increases perceived stress in women compared to men (Bigalke et al., 2020), we found no evidence that there was a significant relationship between the number of children, and changes in the menstrual cycle or in perceived stress in women+ younger than 40. Our data also indicate that anxiety scores were 2 points

higher and depression scores were 2.4 points higher on average in those that reported menstrual cycle disturbances. As can be seen in Figure 1 this was enough of a change to push the average depression scores to mild-moderate depression, however the values for anxiety remain below a clinical diagnosis. Our findings add to the growing body of research on the relationship between pandemic-related stress and menstrual disturbances.

Increased menopause symptoms were associated with increased perceived stress, anxiety and depression

We also found that fewer than ten percent of postmenopausal women+ noticed changes to their menopausal status during the first year of the pandemic. Those who noticed changes in their status reported more menopausal symptoms, and furthermore these individuals were more likely to score higher on perceived stress, depression and anxiety. Perimenopause is thought to be a time of heightened risk for mental health disruption (Schmidt, 2005) and those with menopausal symptoms may be at greater risk to develop psychiatric disorders (Cohen et al., 2006).

The percentage of disturbances in reproductive symptoms was four times greater in our sample of premenopausal (27.8%) compared to postmenopausal women+ (6.7%). It is not clear why this large difference occurred but may be due to age, influence of stress on the HPG axis, or level of stress overall. Indeed, other studies, including data from this same sample, have found that perceived stress, anxiety and depression scores were reduced with increasing age (Brotto et al., 2021; Tang et al., 2022). Thus, our findings of greater premenopausal versus postmenopausal disturbances aligns with data indicating mental health indices were lower for older adults during the first year of the pandemic (Brotto et al., 2021). Hypothalamic-pituitary-adrenal (HPA) axis activation, via stress, initially stimulates, and chronic activation inhibits the HPG resulting in menstrual abnormalities (Toufexis et al., 2014) and as these interactions vary across age (Heck & Handa, 2019; Phumsatitpong et al., 2021), this may also explain our findings as there would have been less HPA activation in the postmenopausal women+ in our sample. However, it is also possible that the premenopausal versus

postmenopausal difference was due, in part, to the differences in the question posed to the two different groups, as our survey asked about menopause status rather than symptoms of menopause.

Relevance and Limitations

Allostatic load, or the cumulative burden of a variety of stressors, affects cardiovascular and metabolic health (Guidi et al., 2021; McEwen, 1998). However, it is important to acknowledge that female-specific factors, such as menstruation and menopause, are also impacted by chronic stress. Others have postulated that female health is cyclical as menstrual patterns correspond to changes in immune system function (Alvergne & Högqvist Tabor, 2018). Moreover, there are specific interactions between gonadal hormones and immune cells (Baker et al., 2004) emphasizing important crosstalk (Arambula & McCarthy, 2020). It is possible that the mechanism behind stress and menstrual changes also involves glucocorticoid receptors in the endometrium (Michael & Papageorghiou, 2008). Although SARS-CoV-2 infection and vaccines use can also disrupt reproductive cycles in the short term (Edelman et al., 2022; Lee et al., 2021), we do not believe this influenced our findings because we found that the seroprevalence of previous infection in this cohort was 2.9% (Racey et al., submitted) and vaccines were not widely available to the general BC population at the time of this survey.

There are limitations to our study. This was a retrospective survey that required online access. However, our findings of high levels of menstrual disturbances is consistent with other studies using data from menstrual tracking apps (Haile et al., 2022). In our survey we did not obtain information on the normal levels of menstrual or menopausal symptoms pre-COVID19 pandemic hence we are only able to cross study comparisons.

This survey was limited to residents of the province of BC and our unique patterns of pandemic restriction measures may have impacted results. We also asked about menopausal status rather than menopausal symptoms and this may have

reduced responses to this population of postmenopausal people. In our survey we also did not clarify why people had suppressed cycles (e.g which type of hormonal contraceptives, gender affirming hormone therapy) which future studies could explore.

We cannot rule out a selection bias in this study, and it is possible that individuals who experienced higher stress pre- and post pandemic were more likely to participate. Similarly, those with menstrual abnormalities may be hyper-aware of their menstrual cycle and led them to participate in the current study.

Conclusions

 The stress associated with the pandemic has impacted both our physical and mental health and our findings suggest that this includes female-specific physical health characteristics. It is imperative to continue advancing the literature on external and internal factors impacting women's reproductive health. Factors that can mitigate against the effects of stress such as social support (Zhao et al., 2019) and exercise (Belgen Kaygısız et al., 2020), which were limited during the initial phases of the pandemic, may have exacerbated the negative outcomes on reproductive cycles for women+. Given the lack of attention to women's health data (Rechlin et al., 2021), more studies examining female-specific health indices are needed in the literature.

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

References Alvergne, A., & Höggvist Tabor, V. (2018). Is Female Health Cyclical? Evolutionary Perspectives on Menstruation. Trends in Ecology & Evolution, 33(6), 399-414. https://doi.org/10.1016/j.tree.2018.03.006 Arambula, S. E., & McCarthy, M. M. (2020). Neuroendocrine-Immune Crosstalk Shapes Sex-Specific Brain Development. Endocrinology, 161(6), bgaa055. https://doi.org/10.1210/endocr/bgaa055 Baker, A. E., Brautigam, V. M., & Watters, J. J. (2004). Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta. Endocrinology, 145(11), 5021–5032. https://doi.org/10.1210/en.2004-0619 Bigalke, J. A., Greenlund, I. M., & Carter, J. R. (2020). Sex differences in self-report anxiety and sleep quality during COVID-19 stay-at-home orders. Biology of Sex Differences, 11(1), 56. https://doi.org/10.1186/s13293-020-00333-4 Brady, E., Nielsen, M. W., Andersen, J. P., & Oertelt-Prigione, S. (2021). Lack of consideration of sex and gender in COVID-19 clinical studies. Nature Communications, 12(1), 4015. https://doi.org/10.1038/s41467-021-24265-8 Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77–101. https://doi.org/10.1191/1478088706qp063oa Brotto, L. A., Chankasingh, K., Baaske, A., Albert, A., Booth, A., Kaida, A., Smith, L. W., Racey, S., Gottschlich, A., Murray, M. C. M., Sadarangani, M., Ogilvie, G. S., & Galea, L. (2021). The influence of sex, gender, age, and ethnicity on psychosocial factors and substance use

461 throughout phases of the COVID-19 pandemic (p. 2021.06.08.21258572). med Rxiv. 462 https://doi.org/10.1101/2021.06.08.21258572 463 Buran, G., & Gercek Öter, E. (2022). Impact of the awareness and fear of COVID-19 on 464 menstrual symptoms in women: A cross-sectional study. Health Care for Women 465 International, 43(4), 413-427. https://doi.org/10.1080/07399332.2021.2004149 466 Ciarambino, T., Para, O., & Giordano, M. (2021). Immune system and COVID-19 by sex 467 differences and age. Women's Health (London, England), 17, 17455065211022262. 468 https://doi.org/10.1177/17455065211022262 Cohen, L. S., Soares, C. N., Vitonis, A. F., Otto, M. W., & Harlow, B. L. (2006). Risk for New Onset 469 470 of Depression During the Menopausal Transition: The Harvard Study of Moods and Cycles. Archives of General Psychiatry, 63(4), 385–390. 471 472 https://doi.org/10.1001/archpsyc.63.4.385 473 Connor, J., Madhavan, S., Mokashi, M., Amanuel, H., Johnson, N. R., Pace, L. E., & Bartz, D. (2020). Health risks and outcomes that disproportionately affect women during the 474 475 Covid-19 pandemic: A review. Social Science & Medicine (1982), 266, 113364. 476 https://doi.org/10.1016/j.socscimed.2020.113364 Core Team, R. (2022). R: A language and environment for statistical computing. R Foundation 477 for Statistical Computing Vienna, Austria. https://www.r-project.org/ 478 479 Demir, O., Sal, H., & Comba, C. (2021). Triangle of COVID, anxiety and menstrual cycle. Journal 480 of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and *Gynaecology*, 41(8), 1257–1261. https://doi.org/10.1080/01443615.2021.1907562 481 482 Edelman, A., Boniface, E. R., Benhar, E., Han, L., Matteson, K. A., Favaro, C., Pearson, J. T., &

Darney, B. G. (2022). Association Between Menstrual Cycle Length and Coronavirus 483 484 Disease 2019 (COVID-19) Vaccination: A U.S. Cohort. Obstetrics & Gynecology, 485 10.1097/AOG.000000000004695. https://doi.org/10.1097/AOG.000000000004695 486 Guidi, J., Lucente, M., Sonino, N., & Fava, G. A. (2021). Allostatic Load and Its Impact on Health: A Systematic Review. Psychotherapy and Psychosomatics, 90(1), 11–27. 487 488 https://doi.org/10.1159/000510696 489 Haile, L., van de Roemer, N., Gemzell-Danielsson, K., Perelló Capó, J., Lete Lasa, I., Vannuccini, 490 S., Koch, M. C., Hildebrandt, T., & Calaf, J. (2022). The global pandemic and changes in women's reproductive health: An observational study. The European Journal of 491 492 Contraception & Reproductive Health Care, O(0), 1–5. https://doi.org/10.1080/13625187.2021.2024161 493 494 Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research 495 electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical 496 *Informatics*, 42(2), 377–381. https://doi.org/10.1016/j.jbi.2008.08.010 497 498 Heck, A. L., & Handa, R. J. (2019). Sex differences in the hypothalamic-pituitary-adrenal axis' 499 response to stress: An important role for gonadal hormones. Neuropsychopharmacology: Official Publication of the American College of 500 Neuropsychopharmacology, 44(1), 45-58. https://doi.org/10.1038/s41386-018-0167-9 501 502 Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008). The link between 503 childhood trauma and depression: Insights from HPA axis studies in humans. Psychoneuroendocrinology, 33(6), 693-710. 504

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

https://doi.org/10.1016/j.psyneuen.2008.03.008 Huang, F. Y., Chung, H., Kroenke, K., Delucchi, K. L., & Spitzer, R. L. (2006). Using the patient health questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. Journal of General Internal Medicine, 21(6), 547–552. Hunt, C., Gibson, G. C., Vander Horst, A., Cleveland, K. A., Wawrosch, C., Granot, M., Kuhn, T., Woolverton, C. J., & Hughes, J. W. (2021). Gender diverse college students exhibit higher psychological distress than male and female peers during the novel coronavirus (COVID-19) pandemic. Psychology of Sexual Orientation and Gender Diversity, 8(2), 238–244. https://doi.org/10.1037/sgd0000461 Kujawa, A., Green, H., Compas, B. E., Dickey, L., & Pegg, S. (2020). Exposure to COVID-19 pandemic stress: Associations with depression and anxiety in emerging adults in the United States. *Depression and Anxiety*, 37(12), 1280–1288. https://doi.org/10.1002/da.23109 Lee, K. M., Junkins, E. J., Fatima, U. A., Cox, M. L., & Clancy, K. B. (2021). Characterizing menstrual bleeding changes occurring after SARS-CoV-2 vaccination (p. 2021.10.11.21264863). medRxiv. https://doi.org/10.1101/2021.10.11.21264863 Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. *Medical Care*, 266–274. Male, V. (2021). Menstrual changes after covid-19 vaccination. BMJ, 374, n2211. https://doi.org/10.1136/bmj.n2211 McEwen, B. S. (1998). Stress, adaptation, and disease. Allostasis and allostatic load. Annals of

527 the New York Academy of Sciences, 840, 33-44. https://doi.org/10.1111/j.1749-528 6632.1998.tb09546.x 529 McEwen, B. S., & Akil, H. (2020). Revisiting the Stress Concept: Implications for Affective Disorders. Journal of Neuroscience, 40(1), 12–21. 530 531 https://doi.org/10.1523/JNEUROSCI.0733-19.2019 532 Michael, A. E., & Papageorghiou, A. T. (2008). Potential significance of physiological and 533 pharmacological glucocorticoids in early pregnancy. Human Reproduction Update, 14(5), 534 497–517. https://doi.org/10.1093/humupd/dmn021 535 Montano, L. T., & Acebes, K. M. L. (2020). Covid stress predicts depression, anxiety and stress 536 symptoms of Filipino respondents. International Journal of Research in Business and Social Science, 9(4), 78–103. https://doi.org/10.20525/ijrbs.v9i4.773 537 538 Nagma, S., Kapoor, G., Bharti, R., Batra, A., Batra, A., Aggarwal, A., & Sablok, A. (2015). To 539 Evaluate the Effect of Perceived Stress on Menstrual Function. Journal of Clinical and 540 Diagnostic Research 2: JCDR, 9(3), QC01–QC03. https://doi.org/10.7860/JCDR/2015/6906.5611 541 542 Nosek, M., Kennedy, H. P., Beyene, Y., Taylor, D., Gilliss, C., & Lee, K. (2010). The effects of 543 perceived stress and attitudes toward menopause and aging on symptoms of 544 menopause. Journal of Midwifery & Women's Health, 55(4), 328–334. https://doi.org/10.1016/j.jmwh.2009.09.005 545 546 Ogilvie, G. S., Gordon, S., Smith, L. W., Albert, A., Racey, C. S., Booth, A., Gottschlich, A., 547 Goldfarb, D., Murray, M. C. M., Galea, L. A. M., Kaida, A., Brotto, L. A., & Sadarangani, M. 548 (2021). Intention to receive a COVID-19 vaccine: Results from a population-based survey 549 in Canada. BMC Public Health, 21(1), 1017. https://doi.org/10.1186/s12889-021-11098-550 9 551 Ozimek, N., Velez, K., Anvari, H., Butler, L., Goldman, K. N., & Woitowich, N. C. (2022). Impact of 552 stress on menstrual cyclicity during the coronavirus disease 2019 pandemic: A survey 553 study. Journal of Women's Health, 31(1), 84-90. 554 Phelan, N., Behan, L. A., & Owens, L. (2021). The Impact of the COVID-19 Pandemic on 555 Women's Reproductive Health. Frontiers in Endocrinology, 12, 642755. 556 https://doi.org/10.3389/fendo.2021.642755 557 Phumsatitpong, C., Wagenmaker, E. R., & Moenter, S. M. (2021). Neuroendocrine interactions 558 of the stress and reproductive axes, Frontiers in Neuroendocrinology, 63, 100928. https://doi.org/10.1016/j.yfrne.2021.100928 559 560 Pieh, C., Budimir, S., & Probst, T. (2020). The effect of age, gender, income, work, and physical 561 activity on mental health during coronavirus disease (COVID-19) lockdown in Austria. Journal of Psychosomatic Research, 136, 110186. 562 https://doi.org/10.1016/j.jpsychores.2020.110186 563 564 Racey, C., Booth, A., Albert, A., Smith, L., Krajden M, M. M., Côté, H., Gottschlich, A., Sadarangani, A., Galea, L., Kaida, A., Brotto, L., & Ogilvie, G. ((Submitted)). Seropositivity 565 566 of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: Cross-sectional 567 survey with dried blood spot samples. BMJ Open. 568 Rechlin, R. K., Splinter, T. F., Hodges, T. E., Albert, A. Y., & Galea, L. A. (2021). Harnessing the 569 power of sex differences: What a difference ten years did not make. BioRxiv. 570 Salari, N., Hosseinian-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M.,

571 Rasoulpoor, S., & Khaledi-Paveh, B. (2020). Prevalence of stress, anxiety, depression 572 among the general population during the COVID-19 pandemic: A systematic review and 573 meta-analysis. Globalization and Health, 16(1), 57. https://doi.org/10.1186/s12992-020-574 00589-w 575 Schmidt, P. J. (2005). Mood, depression, and reproductive hormones in the menopausal 576 transition. The American Journal of Medicine, 118(12, Supplement 2), 54-58. 577 https://doi.org/10.1016/j.amjmed.2005.09.033 Sharp, G. C., Fraser, A., Sawyer, G., Kountourides, G., Easey, K. E., Ford, G., Olszewska, Z., Howe, 578 579 L. D., Lawlor, D. A., Alvergne, A., & Maybin, J. A. (2021). The COVID-19 pandemic and the 580 menstrual cycle: Research gaps and opportunities. *International Journal of* Epidemiology, dyab239. https://doi.org/10.1093/ije/dyab239 581 582 Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, 583 F. E., & Manson, J. E. (2002). Menstrual Cycle Irregularity and Risk for Future Cardiovascular Disease. The Journal of Clinical Endocrinology & Metabolism, 87(5), 584 2013-2017. https://doi.org/10.1210/jcem.87.5.8471 585 586 Souza, F. A. C., Dias, R., Fernandes, C. E., Pimentel, F., & Dias, D. (2010). Menstrual irregularity: A possible clinical marker of metabolic dysfunction in women with class III obesity. 587 588 Gynecological Endocrinology, 26(10), 768–772. https://doi.org/10.3109/09513590.2010.487603 589 590 Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing 591 generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092-592 1097.

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

Tang, Q., Wang, Y., Li, J., Luo, D., Hao, X., & Xu, J. (2022). Effect of Repeated Home Quarantine on Anxiety, Depression, and PTSD Symptoms in a Chinese Population During the COVID-19 Pandemic: A Cross-sectional Study. Frontiers in Psychiatry, 13. https://www.frontiersin.org/article/10.3389/fpsyt.2022.830334 Thurston, R. C., Aizenstein, H. J., Derby, C. A., Sejdić, E., & Maki, P. M. (2016). Menopausal Hot Flashes and White Matter Hyperintensities. Menopause (New York, N.Y.), 23(1), 27–32. https://doi.org/10.1097/GME.0000000000000481 Toufexis, D., Rivarola, M. A., Lara, H., & Viau, V. (2014). Stress and the Reproductive Axis. Journal of Neuroendocrinology, 26(9), 573-586. https://doi.org/10.1111/jne.12179 Trogstad, L. (2022). Increased Occurrence of Menstrual Disturbances in 18- to 30-Year-Old Women after COVID-19 Vaccination (SSRN Scholarly Paper ID 3998180). Social Science Research Network. https://doi.org/10.2139/ssrn.3998180 Viau, V. (2002). Functional Cross-Talk Between the Hypothalamic-Pituitary-Gonadal and -Adrenal Axes. Journal of Neuroendocrinology, 14(6), 506-513. https://doi.org/10.1046/j.1365-2826.2002.00798.x Weidner, K., Bittner, A., Beutel, M., Goeckenjan, M., Brähler, E., & Garthus-Niegel, S. (2020). The role of stress and self-efficacy in somatic and psychological symptoms during the climacteric period—Is there a specific association? *Maturitas*, 136, 1–6. https://doi.org/10.1016/j.maturitas.2020.03.004 Yamamoto, K., Okazaki, A., Sakamoto, Y., & Funatsu, M. (2009). The relationship between premenstrual symptoms, menstrual pain, irregular menstrual cycles, and psychosocial stress among Japanese college students. Journal of Physiological Anthropology, 28(3),

129–136. https://doi.org/10.2114/jpa2.28.129

Yu, M., Han, K., & Nam, G. E. (2017). The association between mental health problems and menstrual cycle irregularity among adolescent Korean girls. *Journal of Affective Disorders*, 210, 43–48. https://doi.org/10.1016/j.jad.2016.11.036

Table 1. Demographic characteristics of respondents. + denotes GenderQueer, Agender, Two-Spirit, other

	Menstr	uation Changes			Posti	menopausal Changes		
Age	Total	No	Yes	P-value	Total	No	Yes	P-value
	No. 1,866	No. 1,347	No. 519		No. 2,305	No. 2,150	No. 155	
25-29	183 (9.8%)	127 (9.4%)	56 (10.8%)	0.14	5 (0.2%)	4 (0.2%)	1 (0.6%)	< 0.0001
30-39	627 (33.6%)	446 (33.1%)	181 (34.9%)		38 (1.6%)	34 (1.6%)	4 (2.6%)	
10-49	808 (43.3%)	602 (44.7%)	206 (39.7%)		174 (7.5%)	151 (7.0%)	23 (14.8%)	
50-59	242 (13.0%)	166 (12.3%)	76 (14.6%)		948 (41.1%)	854 (39.7%)	94 (60.6%)	
60-69	6 (0.3%)	6 (0.4%)	0 (0.0%)		1,140 (49.5%)	1,107 (51.5%)	33 (21.3%)	
		ı		Gender		,		
Woman	1,837 (98.4%)	1,333(99.0%)	504 (97.1%)	0.006	2,283 (99.0%)	2,130 (99.1%	153 (98.7%	0.49
Man	1 (0.1%)	1 (0.1%)	0 (0.0%)		3 (0.1%)	3 (0.1%)	0 (0.0%)	
Non- Binary, GenderQ ueer, Agender, Two- spirit or other	28 (1.5%)	13 (1.0%)	15 (2.9%)		19 (0.8%)	17 (0.8%)	2 (1.3%)	
			In	digenous				
Indigeno us	72 (3.9%)	47 (3.5%)	25 (4.8%)	0.35	52 (2.3%)	47 (2.2%)	5 (3.2%)	0.047
Not ndigeno us	1,706 (91.4%)	1,235 (91.7%)	471 (90.8%)		2,147 (93.1%)	2,008 (93.4%	139 (89.7%	
Prefer not to answer	19 (1.0%)	15 (1.1%)	4 (0.8%)		13 (0.6%)	10 (0.5%)	3 (1.9%)	
Missing	69 (3.7%)	50 (3.7%)	19 (3.7%)		93 (4.0%)	85 (4.0%)	8 (5.2%)	
			Lati	n American				
Latin American	40 (2.1%)	25 (1.9%)	15 (2.9%)	0.21	21 (0.9%)	18 (0.8%)	3 (1.9%)	0.16
Vot	1,819 (97.5%)	1,316 (97.7%)	503 (96.9%)		2,267 (98.4%)	2,118 (98.5%	149 (96.1%	
Missing	7 (0.4%)	6 (0.4%)	1 (0.2%)			14 (0.7%)	3 (1.9%)	

				17 (0.7%)			
		So	uth Asian	17 (0.7%)			
			0.38				0.012
1,800 (96.5%)	1,295 (96.1%)	505 (97.3%)		2,258 (98.0%)	2,112 (98.2%	146 (94.2%	
59 (3.2%)	46 (3.4%)	13 (2.5%)		30 (1.3%)	24 (1.1%)	6 (3.9%)	
7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
			Black				
			0.61				1
19 (1.0%)	15 (1.1%)	4 (0.8%)		8 (0.3%)	8 (0.4%)	0 (0.0%)	
1,840 (98.6%)	1,326 (98.4%)	514 (99.0%)		2,280 (98.9%)	2,128 (99.0%	152 (98.1%	
7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
			White				
			0.044				0.077
368 (19.7%)	281 (20.9%)	87 (16.8%)		245 (10.6%)	222 (10.3%)	23 (14.8%)	
1,491 (79.9%)	1,060 (78.7%)	431 (83.0%)		2,043 (88.6%)	1,914 (89.0%	129 (83.2%	
7 (0.4%)	6 (0.4%)	1 (0.2%)		17 (0.7%)	14 (0.7%)	3 (1.9%)	
		Ec					
1,705 (91.4%)	1,232 (91.5%)	473 (91.1%)	0.93	1,924 (83.5%)	1,788 (83.2%	136 (87.7%	0.18
159 (8.5%)	114 (8.5%)	45 (8.7%)		377 (16.4%)	358 (16.7%)	19 (12.3%)	
2 (0.1%)	1 (0.1%)	1 (0.2%)		4 (0.2%)	4 (0.2%)	0 (0.0%)	
		Number of A	dults in Ho	usehold			
388 (20.8%)	273 (20.3%)	115 (22.2%)	0.65	649 (28.2%)	601 (28.0%)	48 (31.0%)	0.51
364 (19.5%)	263 (19.5%)	101 (19.5%)		526 (22.8%)	488 (22.7%)	38 (24.5%)	
1,113 (59.6%)	810 (60.1%)	303 (58.4%)		1,121 (48.6%)	1,052 (48.9%	69 (44.5%)	
1 (0.1%)	1 (0.1%)	0 (0.0%)		9 (0.4%)	9 (0.4%)	0 (0.0%)	
		Ch	ildren < 5				
			0.095				0.39
1,514 (81.1%)	1,079 (80.1%)	435 (83.8%)		2,225 (96.5%)	2,076 (96.6%	149 (96.1%	
239 (12.8%)	185 (13.7%)	54 (10.4%)		23 (1.0%)	22 (1.0%)	1 (0.6%)	
	59 (3.2%) 7 (0.4%) 19 (1.0%) 1,840 (98.6%) 7 (0.4%) 368 (19.7%) 1,491 (79.9%) 7 (0.4%) 1,705 (91.4%) 159 (8.5%) 2 (0.1%) 388 (20.8%) 364 (19.5%) 1,113 (59.6%) 1 (0.1%)	59 (3.2%) 46 (3.4%) 7 (0.4%) 6 (0.4%) 19 (1.0%) 15 (1.1%) 1,840 (98.6%) 1,326 (98.4%) 7 (0.4%) 6 (0.4%) 368 (19.7%) 281 (20.9%) 1,491 (79.9%) 1,060 (78.7%) 7 (0.4%) 1,232 (91.5%) 159 (8.5%) 114 (8.5%) 2 (0.1%) 1 (0.1%) 388 (20.8%) 273 (20.3%) 364 (19.5%) 263 (19.5%) 1,113 (59.6%) 810 (60.1%) 1 (0.1%) 1 (0.1%) 1,514 (81.1%) 1,079 (80.1%)	1,800 (96.5%) 1,295 (96.1%) 59 (3.2%) 46 (3.4%) 13 (2.5%) 7 (0.4%) 6 (0.4%) 1 (0.2%) 19 (1.0%) 15 (1.1%) 4 (0.8%) 1,840 (98.6%) 1,326 (98.4%) 514 (99.0%) 7 (0.4%) 514 (99.0%) 514 (99.0%) 514 (99.0%) 514 (99.0%) 514 (99.0%) 514 (99.0%) 514 (99.0%) 6 (0.4%) 1 (0.2%) 87 (16.8%) 1,491 (79.9%) 1,060 (78.7%) 431 (83.0%) 7 (0.4%) 6 (0.4%) 1 (0.2%) 1,705 (91.4%) 1,232 (91.5%) 473 (91.1%) 159 (8.5%) 114 (8.5%) 45 (8.7%) 2 (0.1%) 1 (0.1%) 1 (0.2%) Number of A 388 (20.8%) 273 (20.3%) 364 (19.5%) 263 (19.5%) 101 (19.5%) 1 (0.1%) 1 (0.1%) 1 (0.1%) 435 (83.8%) 1,514 (81.1%) 1,079 (80.1%) 435 (83.8%)	1,800 (96.5%) 1,295 (96.1%) 505 (97.3%) 59 (3.2%) 46 (3.4%) 13 (2.5%) 7 (0.4%) 6 (0.4%) 1 (0.2%) 19 (1.0%) 15 (1.1%) 4 (0.8%)	1,800 (96.5%)	1,800 (96.5%)	

more	70 (3.8%)	54 (4.0%)	16 (3.1%)		14 (0.6%)	12 (0.6%)	2 (1.3%)	
Missing	43 (2.3%)	29 (2.2%)	14 (2.7%)		43 (1.9%)	40 (1.9%)	3 (1.9%)	
			Chi	ldren 5-17				
None				0.02				0.004
	996 (53.4%)	698 (51.8%)	298 (57.4%)		1,935 (83.9%)	1,819 (84.6%	116 (74.8%	
One								
One	379 (20.3%)	271 (20.1%)	108 (20.8%)		201 (8.7%)	182 (8.5%)	19 (12.3%)	
Two or	464 (24.9%)							
more		357 (26.5%)	107 (20.6%)		121 (5.2%)	105 (4.9%)	16 (10.3%)	
Missing	27 (1.4%)	21 (1.6%)	6 (1.2%)		48 (2.1%)	44 (2.0%)	4 (2.6%)	
			Chronic H	ealth Condi	tions			
None				0.0003				0.029
	1,026 (55.0%)	776 (57.6%)	250 (48.2%)		998 (43.3%)	944 (43.9%)	54 (34.8%)	
One or	1,020 (33.0%)	770 (37.0%)	230 (48.270)		998 (43.370)	944 (43.970)	34 (34.670)	
more	839 (45.0%)	570 (42.3%)	269 (51.8%)		1,300 (56.4%)	1,199 (55.8%	101 (65.2%	
Missing	1 (0.1%)	1 (0.1%)	0 (0.0%)		7 (0.3%)	7 (0.3%)	0 (0.0%)	
			Crisis	score phase	1			
Mean			Citata	< pnase	1			< 0.00
(SD)	27.8 (±8.0)	26.6 (±7.7)	30.9 (±8.0)	0.0001	24.9 (±7.6)	24.6 (±7.4)	28.9 (±8.8)	
,						, ,		
	63 (3.4%)	51 (3.8%)	12 (2.3%)		86 (3.7%)	78 (3.6%)	8 (5.2%)	
				GAD-7 pho			8 (5.2%)	
Missing				GAD-7 pha			8 (5.2%)	< 0.000
Missing Mean				GAD-7 phas < 0.0001			8 (5.2%) 7.4 (±5.5)	< 0.000
Missing Mean (SD) Missing	63 (3.4%)	51 (3.8%)	Anxiety	<	se 1	78 (3.6%)		< 0.000
Missing Mean (SD)	63 (3.4%) 6.9 (±5.2)	51 (3.8%) 6.2 (±4.9)	8.7 (±5.5) 9 (1.7%)	<	5.0 (±4.7) 106 (4.6%)	78 (3.6%) 4.8 (±4.6)	7.4 (±5.5)	< 0.000
Missing Mean (SD) Missing	63 (3.4%) 6.9 (±5.2)	51 (3.8%) 6.2 (±4.9)	8.7 (±5.5) 9 (1.7%)	< 0.0001	5.0 (±4.7) 106 (4.6%)	78 (3.6%) 4.8 (±4.6)	7.4 (±5.5)	
Missing Mean (SD)	63 (3.4%) 6.9 (±5.2)	51 (3.8%) 6.2 (±4.9)	8.7 (±5.5) 9 (1.7%)	< 0.0001	5.0 (±4.7) 106 (4.6%)	78 (3.6%) 4.8 (±4.6)	7.4 (±5.5)	< 0.000


Table 2. Summary of free-text responses for changes noticed in menstrual cycles. Sample sizes are given and percentages of total sample are given in parentheses.

Theme categories Total n = 92	Themes	Sub-themes	Participant response excerpts		
	Age related n = 15 (51.7)	Entering perimenopause n = 15 (51.7)	"I'm perimenopausal"; "perimenopausal, irregular unpredictable"		
Non-	Changes to medication or contraceptives n = 6 (20.6)	Changes to birth control (patch, pill, IUD) n = 4 (13.7)	"Removed IUD so periods are balancing out" "Started period after going off of birth control"		
Pandemic related n = 29 (31.5)		Medication, supplements n = 2 (6.8)	"— I have recently stopped taking all those supplements and have noticed that my cycle in general is longer"; "Had a period when I had xxx, otherwise I haven't had a period in a while."		
	Changes to reproductive system n = 8 (27.5)	Got pregnant or intended to n = 4 (13.7)	"I got pregnant in xx"; "Stopped due to positive pregnancy test"		
		Hysterectomy n = 4 (13.7)	"Cycle starting to return after ablation"; "Had hysterectomy done in xx"		
	Cycle length/volume changes n = 57 (90.4)	Varying cycle timing (start/end) n = 33 (52.3)	"Cycle is longer. Used to be 28 days. Now 31-32 days."; "My cycle is normally 28 days on average; in March it was 35 days, April 26 day, moving bac to 30 days then 29."		
		Changes in Period Length n = 14 (22.2)	"Irregular. Both long and short"; "Periods have become more irregular, sometimes long, sometimes short with some spotting in between"		
Pandemic control measures n = 63 (68.4)		Volume changes (more or less bleeding) n = 10 (15.80)	"they are more variable shorter, sometimes very light, other quite heavy and with more severe cramps"; "Short, long and light or heavy period. No idea what is happening sort of periods"		
		Mood symptoms	"More mood swings"; "Weird timing and more moody"		
	Periods are more	n = 3 (4.7)			
	symptomatic n = 6 (9.5)	Painful n = 3 (4.7)	"Extreme cramping throughout month of April"; "Worse migraines"		

Table 3. Summary of free-text responses for changes noticed in postmenopausal status. Sample sizes are given and percentages of total sample are given in parentheses.

Theme categories Total n = 111	Themes	Sub-themes	Participant response excerpts
	Surgery n = 10 (45.4)	Hysterectomy/Ovarian cysts n = 10 (45.4)	
Non-pandemic related n = 22 (19.8)	Changes to medication n = 7 (31.8)	Hormone replacement therapy (HRT) changes n = 7 (31.8)	"My postmenopausal symptoms became more severe because of changes in HRT prescription."; "tr(ied) a few replacement medications."
	Pre-existing conditions n = 5 (22.7)	Endometriosis and cancer n = 5 (22.7)	"I had endometrial biopsy xx procedure"; "Bleeding due to bladder cancer"
		Hot flashes and insomnia n = 46 (51.6)	"Hot flashes- haven't had them in years."; "More insomnia and hot flashes, and painful dry eyes which I didn't have before."
	Menopause symptoms	Mood symptoms n = 13 (14.6)	"Felt lonely and depressed and hopeless"; "More emotional and stronger symptoms"
	have worsened n = 69 (77.5)	Vaginal dryness and skin irritation n = 7 (7.8)	"Vaginal dryness, painful sex, sweats"; "More skin irritation"
Pandemic control measures		Headaches/Migraines n = 2 (2.2)	"Migraine headaches, hot flashes"; "Headaches"
n = 89 (80.1)	Irregular changes to health n = 20 (22.4)	Bleeding/abdominal pain n = 9 (10.1)	"One episode of postmenopausal bleeding"; Abdominal pain and cramps in middle lower area."
		Weight changes and hair loss n = 8 (8.9)	"Slower metabolism/weight gain in different areas of body"; "More Uti's"
		Memory loss n = 1 (1.1)	"Memory is getting badfeeling for words often."; "I have felt more symptoms such as brain fog and hot flashes which I assume are hormone related."

Figure 1 Changes to menstrual and menopausal status during early COVID-19 pandemic increased mean CoRonavIruS Health Impact survey (CRISIS) scores, anxiety (GAD-7) and depression symptoms (PHQ-9) in women+. A) Mean (±95%CI) CRISIS scores in women+ with changes to menstrual status were 3.4 points higher. B) Mean (±95%CI) GAD-7 scores in women+ with changes to menstrual status were 2 points higher. C) Mean (±95%CI) PHQ-9 scores in women+ with changes to menstrual status were 2.4 D) Mean(±95%CI) CRISIS scores in women+ with changes to menopausal status were 2.9 points higher. E) Mean (±95%CI) GAD-7 scores in women+ with changes to menopausal status were 1.5 points higher. F) Mean(±95%CI) PHQ-9 scores in women+ with changes to menopausal status were 1.8 points higher. CI=confidence interval. Figure was constructed in R v.4.1.3.



651 Supplement 652 653 1. Are you postmenopausal (have not had a period in 1 year or more)? 654 Yes 655 No 2. [If "No" to guestion 1] Since the COVID-19 pandemic and subsequent public 656 657 health measures in mid-March 2020, have you noticed any changes to your menstrual cycle? 658 659 Yes 660 No Not applicable: I have a suppressed menstrual cycle due to hormonal 661 662 contraception, breast feeding, a medical condition, etc. 663 Not applicable: other 3. [If "yes" to question 2] What changes have you noticed to your menstrual cycle? 664 665 Periods have gotten shorter 666 Periods have gotten longer 667 Periods are more symptomatic (painful, more bleeding, etc.) Periods are less symptomatic 668 669 More periods than normal 670 Fewer periods than normal Other 671 4. [If "other" to question 3] What other changes in your menstrual cycle have you 672 673 noticed since COVID-19?

5. [If "yes" to question 1] Have you noticed any changes to your postmenopausal status since mid-March 2020?

Yes
No

6. [If "yes" to question 5] What changes have you noticed?

Started bleeding again
More menstrual symptoms
Other

7. [If "other" to question 6] Please specify the "Other" changes you have experienced in your postmenopausal status